Moore Capital Management LP purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 87,760 shares of the company's stock, valued at approximately $3,644,000. Moore Capital Management LP owned about 0.19% of Omnicell as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in OMCL. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the second quarter worth $26,000. Versant Capital Management Inc grew its position in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock valued at $44,000 after purchasing an additional 294 shares in the last quarter. Clearstead Advisors LLC increased its stake in Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock valued at $56,000 after buying an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in Omnicell during the 4th quarter worth about $58,000. Finally, Parkside Financial Bank & Trust lifted its position in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock worth $61,000 after buying an additional 1,264 shares in the last quarter. 97.70% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on OMCL shares. KeyCorp restated an "overweight" rating on shares of Omnicell in a report on Monday, August 24th. Wells Fargo & Company reduced their price target on Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Weiss Ratings upgraded Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 18th. Zacks Research lowered Omnicell from a "hold" rating to a "strong sell" rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $57.86.
Check Out Our Latest Research Report on Omnicell
Omnicell Trading Up 6.3%
Omnicell stock opened at $35.16 on Tuesday. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The stock has a market capitalization of $1.60 billion, a P/E ratio of 41.86, a PEG ratio of 0.83 and a beta of 0.98. The stock has a 50-day simple moving average of $39.73 and a 200 day simple moving average of $39.32.
Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same quarter in the prior year, the company earned $0.45 earnings per share. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts expect that Omnicell, Inc. will post 1.41 earnings per share for the current year.
About Omnicell
(
Free Report)
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
